Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Erdmann, E.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk

Erland Erdmann

Medizinische Klinik III der Universität zu Köln, Kerpener Str. 62, D-50937 Köln, Germany, erland.erdmann{at}uni-koeln.de

People with type 2 diabetes carry an excess burden of cardiovascular risk that warrants close attention to risk factors in the majority of patients. Despite multifactorial intervention, often including statin therapy, a substantial residual risk remains, highlighting the need for novel therapies. Thiazolidinediones (TZDs) are activators of the peroxisome proliferator-activated receptor-gamma that have multiple potentially beneficial effects on established and emerging metabolic risk factors. Available evidence suggests that, even in the presence of statin therapy, TZDs can improve risk factor profiles, reduce atherosclerosis and have a beneficial effect on cardiovascular outcomes. This article reviews the evidence supporting the use of therapy combining a TZD with a statin in patients with type 2 diabetes.

Key Words: cardiovascular risk reduction • thiazolidinediones • type 2 diabetes • statins.

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 5, 211-216 (2007)
DOI: 10.1177/14746514070070050301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?